These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 21499747

  • 1. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study.
    Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, Nappi G.
    J Headache Pain; 2011 Aug; 12(4):427-33. PubMed ID: 21499747
    [Abstract] [Full Text] [Related]

  • 2. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
    Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, BOTOX CDH Study Group.
    Headache; 2005 Apr; 45(4):293-307. PubMed ID: 15836565
    [Abstract] [Full Text] [Related]

  • 3. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 4. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, BOTOX CDH Study Group.
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [Abstract] [Full Text] [Related]

  • 5. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group.
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [Abstract] [Full Text] [Related]

  • 6. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC, BoNTA-039 Study Group.
    Mayo Clin Proc; 2005 Sep; 80(9):1126-37. PubMed ID: 16178492
    [Abstract] [Full Text] [Related]

  • 7. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group.
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [Abstract] [Full Text] [Related]

  • 8. [Botulinum toxin type A (Relatox) in the treatment of chronic migraine in adults: results of phase IIIb, randomized, one-blind, multicenter, active-controlled, parallel-group trial].
    Artemenko AR, Abramov VG, Konovalova ZN, Korenko AN, Krasavina DA, Kurenkov AL, Latysheva NV, Naprienko MV, Orlova OR, Filatova EG, Shevchenko VS, Yakovleva PN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023 Jun; 123(5):89-99. PubMed ID: 37315247
    [Abstract] [Full Text] [Related]

  • 9. [Botulinum toxin type A (Relatox) in transition from medication overuse to non-overuse status in patients with chronic migraine: a subgroup analysis of phase IIIb randomized single-blind multicenter active-controlled parallel-group trial].
    Artemenko AR, Abramov VG, Bozhenkina TV, Konovalova ZN, Korenko AN, Krasavina DA, Kurenkov AL, Latysheva NV, Naprienko MV, Orlova OR, Filatova EG, Shevchenko VS, Iakovleva PN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023 Jun; 123(11):64-74. PubMed ID: 37994890
    [Abstract] [Full Text] [Related]

  • 10. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
    Mathew NT, Kailasam J, Meadors L.
    Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
    [Abstract] [Full Text] [Related]

  • 11. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 12. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.
    J Neurol Sci; 2013 Aug 15; 331(1-2):48-56. PubMed ID: 23790235
    [Abstract] [Full Text] [Related]

  • 13. Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type A?
    Butera C, Colombo B, Bianchi F, Cursi M, Messina R, Amadio S, Guerriero R, Comi G, Del Carro U.
    Neurol Sci; 2016 Oct 15; 37(10):1701-6. PubMed ID: 27395386
    [Abstract] [Full Text] [Related]

  • 14. Onabotulinum toxin A treatment of cervicogenic headache: a randomised, double-blind, placebo-controlled crossover study.
    Linde M, Hagen K, Salvesen Ø, Gravdahl GB, Helde G, Stovner LJ.
    Cephalalgia; 2011 May 15; 31(7):797-807. PubMed ID: 21300635
    [Abstract] [Full Text] [Related]

  • 15. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
    Christie SN, Giammarco R, Gawel M, Mackie G, Gladstone J, Becker WJ.
    Can J Neurol Sci; 2010 Sep 15; 37(5):588-94. PubMed ID: 21059503
    [Abstract] [Full Text] [Related]

  • 16. Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study.
    Rollnik JD, Tanneberger O, Schubert M, Schneider U, Dengler R.
    Headache; 2000 Apr 15; 40(4):300-5. PubMed ID: 10759934
    [Abstract] [Full Text] [Related]

  • 17. The use of onabotulinum toxin A (Botox(®)) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study.
    Russo M, Manzoni GC, Taga A, Genovese A, Veronesi L, Pasquarella C, Sansebastiano GE, Torelli P.
    Neurol Sci; 2016 Jul 15; 37(7):1127-31. PubMed ID: 27048312
    [Abstract] [Full Text] [Related]

  • 18. Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study.
    Ondo WG, Simmons JH, Shahid MH, Hashem V, Hunter C, Jankovic J.
    Neurology; 2018 Feb 13; 90(7):e559-e564. PubMed ID: 29343468
    [Abstract] [Full Text] [Related]

  • 19. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders.
    Blumenfeld A.
    Headache; 2003 Sep 13; 43(8):853-60. PubMed ID: 12940806
    [Abstract] [Full Text] [Related]

  • 20. Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraine.
    Bruloy E, Sinna R, Grolleau JL, Bout-Roumazeilles A, Berard E, Chaput B.
    Plast Reconstr Surg; 2019 Jan 13; 143(1):239-250. PubMed ID: 30589800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.